Rafferty Asset Management, LLC Inhibrx, Inc. Transaction History

Rafferty Asset Management, LLC

$26.7 Billion
Q1 2024

A detailed history of Rafferty Asset Management, LLC transactions in Inhibrx, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 201,948 shares of INBX stock, worth $2.86 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

201,948

Previous 103,246 95.6%

Holding current value

$2.86 Million

Previous $3.92 Million 79.96%

% of portfolio

0.03%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$32.76 - $39.56 $3.23 Million - $3.9 Million	98,702 Added 95.6%	201,948 $7.06 Million
Q4 2023 Feb 13, 2024	SELL	$14.5 - $38.0 $182,439 - $478,116	-12,582 Reduced 10.86%	103,246 $3.92 Million
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $259,182 - $432,957	-16,456 Reduced 12.44%	115,828 $2.13 Million
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $385,653 - $632,598	-22,739 Reduced 14.67%	132,284 $3.43 Million
Q1 2023 May 11, 2023	SELL	$18.45 - $27.14 $770,638 - $1.13 Million	-41,769 Reduced 21.22%	155,023 $2.93 Million

Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $1.29 Million - $2.13 Million	63,793 Added 47.97%	196,792 $4.85 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $1.54 Million - $3.29 Million	132,999 New	132,999 $2.39 Million
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $809,689 - $2.4 Million	-95,034 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $1.12 Million - $2.42 Million	56,121 Added 144.22%	95,034 $2.12 Million
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $1.04 Million - $1.79 Million	38,913 New	38,913 $1.7 Million

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Inhibrx, Inc. Transaction History